Oxidative Medicine and Cellular Longevity

Cardiotoxicity of Antineoplastic Agents: From Basic Research to Clinical Practice


Publishing date
01 Jan 2023
Status
Published
Submission deadline
19 Aug 2022

Lead Editor
Guest Editors

1Beijing University of Chinese Medicine, Beijing, China

2Tianjin University of Traditional Chinese Medicine, Tianjin, China

3Mayo Clinic, Minnesota, USA


Cardiotoxicity of Antineoplastic Agents: From Basic Research to Clinical Practice

Description

Cardio-oncology is a new and growing interdisciplinary field dedicated to the coordination and improvement of care of cancer patients and survivors by cardiologists, oncologists, and primary care providers. The field has quickly evolved due to the increasing understanding in the clinical and research communities that cancer treatments, although potentially life-saving, may also cause serious cardiac adverse effects, known as cardiotoxicities. These potentially dangerous, unintended effects, in turn, represent a major cause of morbidity and death in cancer survivors without effective therapeutic strategies to date. Virtually all antineoplastic agents are associated with cardiotoxicity, which can be divided into 5 categories: direct cytotoxic effects of chemotherapy and associated cardiac systolic dysfunction, cardiac ischemia, arrhythmias, pericarditis, and chemotherapy-induced repolarization abnormalities.

Research in antineoplastic agents-induced cardiotoxicity includes the prevention, diagnosis, and treatment of these complications in cancer patients. It also aims at elucidating the mechanisms involved in cardiotoxicity and cardio-protection, leading to the identification of novel targets for drug discovery. Over the past few decades, cardio-oncology has shed light on the mechanisms by which widely used anti-cancer drugs, such as anthracyclines and anti-HER2 monoclonal antibodies, cause heart failure (HF), and on the potential cardioprotective effects of molecules such as dexrazoxane. Nevertheless, the molecular events behind the cardiotoxicity of the next generation of oncological treatments, like immune checkpoint inhibitors, are not completely understood, and new anti-cancer therapies are continuously marketed. These limitations in our knowledge prevent from us finding specific and effective strategies to diagnose, prevent and treat HF secondary to cancer therapy-related cardiotoxicity.

This Special Issue encourages submissions related to the pathophysiology, prevention, diagnosis, and treatment (both western medicine and natural products) of the cardiotoxic effects of cancer therapies, from basic mechanistic studies to translational, preclinical, and clinical research, including clinical trials, outcomes studies, case reports, and imaging techniques. We welcome original research and review articles.

Potential topics include but are not limited to the following:

  • Biomarkers and the susceptibility of cancer patients to cardiovascular injury
  • Identification of shared mechanisms as well as common risk factors of cancer and HF
  • Understanding the role of intercellular cross-talks in the development of cardiotoxicity
  • Development of powerful in vitro and in vivo models for the study of the interaction between cancer and HF as well as cardiotoxicity of oncological treatments
  • Robust preclinical models to determine cardiovascular toxicity (shortcomings of current preclinical testing and correlation of the preclinical models with the clinic output)
  • Cardioprotective signaling
  • Mechanisms of the cardiotoxicity of anticancer drugs (e.g. epigenetic alterations, genomic instability, loss of proteostasis, mitochondrial functions, metabolic alterations)
  • Prevention and treatment strategies (e.g. dose changes for chemotherapy)
  • Cardioprotective drug discovery (e.g. development of new leads based on phenotypic screening or targeting a defined molecular target, drug repositioning)
  • Studies and reviews on the use of large genomic, proteomic and metabolomic databases (“big data in cardio-oncology”)

Articles

  • Special Issue
  • - Volume 2023
  • - Article ID 7872193
  • - Research Article

RING Finger Protein 10 Regulates AP-1/Meox2 to Mediate Pirarubicin-Induced Cardiomyocyte Apoptosis

Hongwei Shi | Liang Duan | ... | Heng Tang
  • Special Issue
  • - Volume 2022
  • - Article ID 7176282
  • - Review Article

Mechanisms and Drug Intervention for Doxorubicin-Induced Cardiotoxicity Based on Mitochondrial Bioenergetics

Guanjing Ling | Xiaoping Wang | ... | Yong Wang
  • Special Issue
  • - Volume 2022
  • - Article ID 6430342
  • - Review Article

The Mitochondrial Unfolded Protein Response: A Novel Protective Pathway Targeting Cardiomyocytes

Jinfeng Liu | Xinyong He | ... | Junyan Wang
  • Special Issue
  • - Volume 2022
  • - Article ID 3659278
  • - Review Article

The Role of Mitochondrial Quality Control in Anthracycline-Induced Cardiotoxicity: From Bench to Bedside

Yukun Li | Rong Lin | ... | Nian Liu
  • Special Issue
  • - Volume 2022
  • - Article ID 2852251
  • - Review Article

Understanding the Protective Role of Exosomes in Doxorubicin-Induced Cardiotoxicity

Guoxia Zhang | Xinyu Yang | ... | Yanwei Xing
  • Special Issue
  • - Volume 2022
  • - Article ID 3617086
  • - Review Article

Protective Effect of Natural Medicinal Plants on Cardiomyocyte Injury in Heart Failure: Targeting the Dysregulation of Mitochondrial Homeostasis and Mitophagy

Qi Wang | Hao Su | Jinfeng Liu
  • Special Issue
  • - Volume 2022
  • - Article ID 4344677
  • - Research Article

Qishen Granule Protects against Doxorubicin-Induced Cardiotoxicity by Coordinating MDM2-p53-Mediated Mitophagy and Mitochondrial Biogenesis

Weili Li | Yawen Zhang | ... | Yong Wang
  • Special Issue
  • - Volume 2022
  • - Article ID 5104351
  • - Research Article

Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy

Xu Han | Fei Liu | ... | Yunlong Xia
  • Special Issue
  • - Volume 2022
  • - Article ID 6260243
  • - Research Article

Current Status and Trends of Research on Anthracycline-Induced Cardiotoxicity from 2002 to 2021: A Twenty-Year Bibliometric and Visualization Analysis

Yu Wang | Yifei Rao | ... | Bing Zhang
  • Special Issue
  • - Volume 2022
  • - Article ID 5818612
  • - Review Article

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity

Yonghe Ding | Ke Du | ... | Xiaolei Xu
Oxidative Medicine and Cellular Longevity
 Journal metrics
See full report
Acceptance rate9%
Submission to final decision179 days
Acceptance to publication36 days
CiteScore10.100
Journal Citation Indicator-
Impact Factor-
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.